Preventing or reducing the symptoms of lactose intolerance in an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75 pcnt by weight beta-casein A2. The effect is both acute (post-exposure to the composition) and ongoing (future exposure to lactose).